BII Ready to Invest DKK 70M in HealthTech

BII Copenhagen

writer icon Carsten Kristensen     ISB   |   Investment     🕐 14. Jul. 2020

BioInnovation Institute is increasing its focus on early-stage projects and startups in health tech by allocating up to DKK 70M annually to this area.

New Strategy
The commitment is part of a new strategy to help foster scientific-based innovations in health tech that usually require considerable investments before reaching the market.

”The areas of digital medicine, advanced diagnostics and digital platforms will be our areas of focus. Despite the promises of digital technologies in healthcare and life sciences, the lack of solid clinical validation and limited customer adoption are still amongst the significant challenges and this is where we will invest”, said Markus Herrgård, Chief Technical Officer at BioInnovation Institute.

First Investment
With the new commitment to health tech, Professor Anja Boisen from the Technical University of Denmark (DTU) will be the first to lead a group in this area in the BII Faculty.

Boisen has been awarded DKK 18M paid in three tranches over the coming three years to develop a miniaturised tabletop device that can perform therapeutic drug monitoring on a single drop of blood in a matter of minutes.

The group will be working on a solution available at point of care without the need for specialised personnel and at a fraction of the currently available cost.

“The partnership with BII is truly unique. It is not only a large grant but also very valuable for us to work with experts in business development from such an early stage”, said Professor Anja Boisen, who has extensive experience in academia and commercialisation.

Boisen's Background
Boisen has worked with sensor development for more than 20 years and managed several larger national and international projects.

Today, she is heading the IDUN centre of Excellence and has co-founded four spinout companies from DTU. Boisen has worked in industry collaborations with companies such as Grundfos, Virogates, Coloplast and Radiometer, and her students have won more than 15 Venture Prizes.

The Project
As part of the BII Faculty, Boisen will establish a group at BioInnovation Institute lead by Senior Scientist Kinga Zor to work on the development of the device.

Kinga Zor will be the daily manager of the project and in charge of the assay development.

“Advanced diagnostics is key in the development of our global health care system and Anja Boisen has proven herself for many years in academia and shown to have a great understanding of commercialisation, which is key for BII. We are very pleased to see her in the BII Faculty”, said Markus Herrgård.

Boisen's team joined BII two weeks ago, alongside Professor Morten Alexander Sommer and DTU Scientific Director and Professor at the University of California, Berkeley, Jay Keasling, who has been working with BII since the beginning of 2020.

We believe that information should be free and will therefore never put up a paywall.

If you like reading our reports about the Scandinavian business scene and would like to donate towards the upkeep of the site, we would be very grateful. Click here to donate.

Most Popular Articles of November

Most Popular Articles of this Year